Microbial products and bacterial infections may stimulate disease progression in CTCL because both, strong activation of STAT-3 and high expression of IL-10, were identified as markers of poor response to treatment in CTCL [30]. This evidence concerns the gene STAT3 and bacterial infectious disease.